Metropolitan Life Insurance CO Cyma Bay Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

38 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $9,838 - $19,062	779 Added 13.74%	6,447 $152,000
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $3,258 - $5,286	300 Added 5.59%	5,668 $84,000
Q2 2023 Aug 10, 2023	BUY	$7.47 - $10.95 $40,098 - $58,779	5,368 New	5,368 $58,000
Q2 2022 Aug 11, 2022	SELL	$1.72 - $3.39 $10,547 - $20,787	-6,132 Closed	0 $0
Q1 2022 Jun 20, 2023	BUY	$2.77 - $3.64 $16,985 - $22,320	6,132 New	6,132 $19,000
Q1 2022 Mar 30, 2023	SELL	$2.77 - $3.64 $38,527 - $50,628	-13,909 Reduced 69.4%	6,132 $19,000
Q1 2022 May 12, 2022	BUY	$2.77 - $3.64 $16,985 - $22,320	6,132 New	6,132 $19,000
Q4 2021 Feb 15, 2022	SELL	$3.23 - $4.6 $64,732 - $92,188	-20,041 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$3.47 - $4.42 $69,542 - $88,581	20,041 New	20,041 $73,000
Q3 2021 Mar 30, 2023	SELL	$3.47 - $4.42 $8,196 - $10,440	-2,362 Reduced 10.54%	20,041 $73,000
Q3 2021 Nov 15, 2021	BUY	$3.47 - $4.42 $69,542 - $88,581	20,041 New	20,041 $73,000
Q2 2021 Aug 16, 2021	SELL	$3.94 - $4.92 $86 - $108	-22 Closed	0 $0
Q1 2021 Jun 26, 2023	BUY	$4.23 - $6.55 $94,764 - $146,739	22,403 New	22,403 $102 Million
Q1 2021 Mar 30, 2023	BUY	$4.23 - $6.55 $49,867 - $77,217	11,789 Added 111.07%	22,403 $101,000
Q1 2021 May 14, 2021	SELL	$4.23 - $6.55 $44,804 - $69,377	-10,592 Reduced 99.79%	22 $102,000
Q4 2020 Jun 22, 2023	BUY	$5.73 - $9.03 $60,818 - $95,844	10,614 New	10,614 $60,000
Q4 2020 Mar 30, 2023	SELL	$5.73 - $9.03 $24,392 - $38,440	-4,257 Reduced 28.63%	10,614 $60,000
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $24,392 - $38,440	-4,257 Reduced 28.63%	10,614 $61,000
Q3 2020 Jun 26, 2023	BUY	$3.32 - $7.24 $49,371 - $107,666	14,871 New	14,871 $107,000
Q3 2020 Mar 30, 2023	SELL	$3.32 - $7.24 $30,550 - $66,622	-9,202 Reduced 38.23%	14,871 $107,000
Q3 2020 Nov 13, 2020	SELL	$3.32 - $7.24 $30,550 - $66,622	-9,202 Reduced 38.23%	14,871 $108,000
Q2 2020 Jun 26, 2023	BUY	$1.41 - $4.25 $33,942 - $102,310	24,073 New	24,073 $84,000
Q2 2020 Mar 30, 2023	BUY	$1.41 - $4.25 $4,898 - $14,764	3,474 Added 16.86%	24,073 $84,000
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $33,942 - $102,310	24,073 New	24,073 $84,000
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $27,396 - $122,152	-20,599 Closed	0 $0
Q3 2019 Jul 12, 2023	BUY	$5.12 - $7.21 $105,466 - $148,518	20,599 New	20,599 $105,000
Q3 2019 Mar 30, 2023	BUY	$5.12 - $7.21 $3,578 - $5,039	699 Added 3.51%	20,599 $105,000
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $3,578 - $5,039	699 Added 3.51%	20,599 $105,000
Q2 2019 Jul 12, 2023	BUY	$6.05 - $13.66 $120,395 - $271,834	19,900 New	19,900 $142,000
Q1 2019 Jul 13, 2023	BUY	$8.16 - $13.42 $162,384 - $267,058	19,900 New	19,900 $264,000
Q1 2019 Mar 30, 2023	BUY	$8.16 - $13.42 $162,384 - $267,058	19,900 New	19,900 $264,000
Q1 2019 May 16, 2019	SELL	$8.16 - $13.42 $98,075 - $161,294	-12,019 Reduced 37.65%	19,900 $264,000
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $98,075 - $161,294	12,019 Added 60.4%	31,919 $2.35 Million
Q4 2018 Jul 13, 2023	BUY	$6.54 - $11.74 $130,146 - $233,626	19,900 New	19,900 $156,000
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $101,644 - $182,463	15,542 Added 356.63%	19,900 $157,000
Q3 2018 Jul 13, 2023	BUY	$10.88 - $14.52 $216,512 - $288,948	19,900 New	19,900 $220 Million
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $169,096 - $225,669	-15,542 Reduced 78.1%	4,358 $48,000
Q2 2018 Aug 15, 2018	BUY	$10.66 - $14.38 $212,134 - $286,162	19,900 New	19,900 $0

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account